Genetic basis for clinical response to CTLA-4 blockade in melanoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • CTLA-4 Antigen
  • Melanoma
  • Skin Neoplasms

abstract

  • These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4315319

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1406498

PubMed ID

  • 25409260

Additional Document Info

start page

  • 2189

end page

  • 99

volume

  • 371

number

  • 23